Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Mar 18, 2023

Editas Medicine (EDIT, $8.37) was a top loser this quarter, falling -18.5%

Over the last three months, Editas Medicine (EDIT) has been a top loser in the biotechnology industry, falling by 18.5% to $8.37 per share. This information was gathered by A.I.dvisor, which analyzed 968 stocks in the biotechnology industry for the 3-month period ending March 17, 2023, and found that 60.19% of them demonstrated a downtrend, while only 39.81% exhibited an uptrend.

However, there is some positive news for EDIT as it is currently in an upward trend. The price of EDIT may ascend as a result of having broken its lower Bollinger Band on March 10, 2023. This means that EDIT may jump back above the lower band and head towards the middle band. Traders may consider buying the stock or exploring call options.

It is interesting to note that in 29 out of 32 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. This means that the odds of a continued upward trend are quite high, at 90%.

Despite EDIT's recent losses, the company's potential to impact the biotechnology industry is significant. Editas Medicine is a leading genome editing company that uses CRISPR technology to develop new therapies for genetic diseases. The company's pipeline includes treatments for a range of diseases, including sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy.

In addition to its pipeline, Editas Medicine has partnerships with major pharmaceutical companies such as Allergan and Juno Therapeutics. These partnerships help to provide the company with funding and resources to continue its research and development efforts.

Overall, while EDIT may have experienced losses over the last three months, the company's potential for growth is significant. 

Related Ticker: EDIT

EDIT's Indicator enters downward trend

The Aroon Indicator for EDIT entered a downward trend on July 12, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 304 similar instances where the Aroon Indicator formed such a pattern. In of the 304 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on July 17, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

EDIT moved below its 50-day moving average on July 18, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on July 16, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 10, 2024. You may want to consider a long position or call options on EDIT as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on July 09, 2024. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for EDIT crossed bullishly above the 50-day moving average on July 19, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 81%.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.455) is normal, around the industry mean (12.608). P/E Ratio (0.000) is within average values for comparable stocks, (157.727). EDIT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.453). Dividend Yield (0.000) settles around the average of (0.064) among similar stocks. P/S Ratio (5.945) is also within normal values, averaging (215.699).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.93B. The market cap for tickers in the group ranges from 151 to 589.54B. NONOF holds the highest valuation in this group at 589.54B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 12%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 19%. SCPXD experienced the highest price growth at 12,208%, while ASLN experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -28%. For the same stocks of the Industry, the average monthly volume growth was -43% and the average quarterly volume growth was 56%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 50
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
EDIT
Daily Signal changed days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
The Tickeron quant team is delighted to introduce our best robot of the week tailored for Trend Traders. Our sophisticated AI Robot, has been designed for manual trading enthusiasts who value independent signal selection.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
The Tickeron quant team proudly presents our top-performing AI robot for swing traders. This robot stands out with its remarkable accuracy, empowering traders to capitalize on diverse market conditions and transaction types. Demonstrating its proficiency, it achieved profitability in short trades during last week's strong uptrend in the US stock markets.
One such example is the "Trend Trader: Popular Stocks (TA&FA)" platform, where AI trading robots demonstrated their prowess by generating a notable gain while actively trading Adobe Inc. (ADBE) over the previous week. In this article, we delve into a technical analysis of ADBE's recent performance, shedding light on key indicators and recent earnings results.
​​​​​​​The railroads sector, encompassing prominent players such as Canadian Pacific Railway (CP), CSX Corporation (CSX), Norfolk Southern Corporation (NSC), Canadian National Railway Company (CNI), and Union Pacific Corporation (UNP), has undergone a noteworthy surge in performance over the past week. However, a closer examination reveals a complex landscape marked by negative outlook signals and fluctuating market dynamics.
The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.
In the whirlwind of the current mergers and acquisitions frenzy, investors are reaping substantial rewards as stocks within the merger industry theme surged by an impressive 20.9% on average over the past month.
The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.
In the dynamic landscape of the US stock markets, where unpredictability has become the norm, finding a trading strategy that not only thrives in periods of growth but also shields against sharp corrections is paramount.
The Tickeron quant team proudly introduces our premier AI Robot, tailor-made for trend traders who prefer manual trading and selecting their own signals. This AI Robot stands out with its impressive track record of consistent trading predictions, empowering traders to align their decisions with personal preferences.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week, given the recent downturn in major US stock indices. While the SP500, NASDAQ 100, and Dow Jones Industrial all experienced declines, our AI robot, thanks to its well-calibrated diversification across various industries, demonstrated remarkable resilience.
As the trading week came to a close on Friday, there were notable movements across various asset classes:
Tickeron's quant team diligently monitors developed trading algorithms daily to determine the most effective ones. Today, we are delighted to present three of the best robots tailored for swing traders, showcasing consistently positive results over several months, irrespective of market conditions. This week, they underscored their efficacy by yielding impressive gains across various stocks, even as major US stock indexes dipped.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week. The US stock market has experienced a consistent upward trend for the past five months, heightening the anticipation of a forthcoming correction with each passing day.
Introducing our top-performing best AI Robot of the week, designed by Tickeron's expert quant team for trading small-cap stocks. This algorithm blends classical and proprietary technical indicators, honed through advanced machine learning, to empower users with effective portfolio diversification and maximum profitability in the dynamic market.